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Accepted 7 April 2015Dietary supplementation with folic acid (FA) has been shown to induce opposing effects on
cancer-related outcomes. The mechanism underlying such heterogeneity is unclear. We
hypothesized that FA supplementation induces changes in breast cancer–associated (BRCA)
genes 1 and 2 expression and function through altered epigenetic regulation in a cell type–
dependent manner. We investigated the effect of treating normal and cancer cells with
physiologically relevant FA concentrations on the mRNA and protein expression, capacity
for DNA repair, and DNA methylation of BRCA1 and BRCA2. FA treatment induced dose-
related increases in BRCA1 mRNA expression in HepG2, Huh-7D12, Hs578T, and JURKAT
and in BRCA2 in HepG2, Hs578T, MCF7, and MDA-MB-157 cells. FA did not affect the
corresponding normal cells or on any of the ovarian cell lines. Folic acid induced increased
BRCA1 protein expression in Hs578T, but not HepG2 cells, whereas BRCA2 protein levels
were undetectable. FA treatment did not alter DNA repair in liver-derived cells, whereas
there were transient effects on breast-derived cells. There was no effect of FA treatment on
BRCA1 or BRCA2 DNA methylation, although there was some variation in the methylation
of specific CpG loci between some cell lines. Overall, these findings show that the effects of
FA on BRCA-related outcomes differ between cells lines, but the biological consequences of
induced changes in BRCA expression appear to be at most limited.
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Folic acid (FA) is the synthetic form of folate that is used
widely as a nutritional supplement or in dietary fortification.
The effect of FA on cancer risk is unclear, and there are
conflicting reports that suggest that FA intake is either
associated with increased or decreased risk of cancer, in
particular colorectal cancer [1]. FA fortification has been
associated with a lower incidence of neuroblastoma, but had
no effect on lymphoblastic leukemia or hepatoblastoma [2].
Maternal FA intake has been associated negatively with risk
of childhood neuroectodermal tumors [3] and neuroblastoma
[4]. In adults, supplementation with 5 mg FA per day reduced
reoccurrence of adenomas by 56% [5] compared with placebo,
whereas cosupplementation of FA and aspirin had no
significant effect on reoccurrence [6,7]. The extent to which
such effects are associative rather than causal is unclear [8].
Furthermore, the incidence of colorectal cancer in the United
States and Canada appeared to increase transiently after the
introduction of mandatory FA fortification [9]. This positive
association between FA and risk of colon cancer is supported
by an increase in incidence by 2.6 to 2.9 between pre- and
postintroduction of FA fortification in Chile [10]. In contrast,
FA intake was negatively associated with colorectal cancer
risk in a case-cohort study of 5629 women [11]. A meta-
analysis of randomized controlled trials of FA supplementa-
tion based on 13 studies failed to show a significant effect on
total cancer incidence or the incidence of specific cancers [12].
Women who received a supplement containing FA and
vitamins B12 and B6 showed reduction in risk of total invasive
cancer and of breast cancer, although these effects were not
statistically significant [13]. Although such heterogeneitymay
reflect differences between study cohorts and between the
design of the intervention, and level of FA given, it is also
possible that different tissues or cancer subtypesmay differ in
their response to FA.
Tetrahydrofolate is the biologically active metabolite of FA
and is a cofactor for the rate-limiting reaction in the supply of
methyl groups to the homocysteine/methionine remethylation
cycle inwhichDNA is a terminal acceptor. Epigenetic regulation
of transcription by DNA methylation involves differential
methylation of CpG dinucleotides in gene promoters as well
as covalentmodifications of histones and noncoding RNAs [14].
Methylation of gene promoters is a relatively stable epigenetic
mark that is induced during development. However, some
genes retain epigenetic plasticity beyond early development
and are susceptible to interventions in later life, including FA
intake [15]. Furthermore, aging is associated with carcinogen-
esis with both global hypomethylation and hypermethylation
of tumor suppressor genes [16]. Diets lowor enriched in FAhave
been shown to induce altered DNAmethylation in experimen-
talmodels [17–20] and inhumans [21]. Thus, variations in folate
status or FA intake may modify cancer risk by altering the
epigenetic regulation of genes.
The breast cancer–associated (BRCA) genes 1 and 2 are
tumor suppressor genes with several key functions related to
maintaining DNA integrity [22]. The proteins encoded by
these genes are expressed in all cells and are critical for repair
of single- and double-stranded DNA breaks. Mutations in theBRCA1 and BRCA2 genes have been implicated primarily in
the development of breast and ovarian cancers, but germline
mutation carriers of BRCA1 and BRCA2 also have a small
increased risk of stomach, pancreas, prostate, and colon
cancer [23]. Impaired BRCA1 and BRCA2 activities lead to
gross chromosomal rearrangements and gene dysregulation
[22]. Approximately 90% of cases of breast and ovarian cancer
are sporadic and are not associated with mutations in the
BRCA genes [24]. In these cases, reduced BRCA1 activity
involves hypermethylation of its promoter leading to tran-
scriptional repression [25–29]. In contrast, the BRCA2 promot-
er has been shown to be hypomethylated and overexpressed
in ovarian cancers compared with normal tissue [29]. Thus,
one possible additional source of heterogeneity in the effects
of FA on cancer risk is the differential effects on the epigenetic
regulation of BRCA1 and BRCA2 leading to genomic instability
[30–32]. In order to inform nutritional guidelines about FA
intake and cancer risk, it is important to know if FA
supplementation induces differential effects on the epigenet-
ic regulation of BRCA1 and BRCA2, and whether such effects
are specific to individual tissues or cancer subtypes and if
such effects differ between cancer and normal cells.
We tested the hypothesis that treatment with FA induces
differential effects of the epigenetic regulation of BRCA1 and
BRCA2 transcription leading to variation between cell types in
capacity for DNA repair. To address this, normal and cancer
cells were treated in vitro with concentrations of FA that were
within the range of unmetabolized FA in plasma (0-100 nmol/L)
[33–37] reported in humans taking 200 μg/day FAormore on the
mRNA expression of BRCA1 and BRCA2. Cells arising from
different tissues were tested to determine whether any effects
of FA on BRCA1 and BRCA2 were specific to a specific cancer
type or subtype. To determine whether any changes in BRCA1
or BRCA2mRNA expressionwere associated altered function of
these genes, we investigated the effect of FA treatment on
BRCA1 and BRCA2 protein expression and on the DNA
methylation of their promoters, and on capacity of cells to
repair radiation-induced DNA damage.2. Methods and materials
2.1. Cell lines
SK-HEP-1 human liver adenocarcinoma, PLC/PRF/5 human
liver hepatoma, Huh-7D12 human hepatocellular carcinoma,
HMT-3522 S1 human breast epithelia, Hs578T human breast
adenocarcinoma, MDA-MB-157 human breast medulla carci-
noma, MDA-MB-231 human breast adenocarcinoma, A2780
human ovarian carcinoma, COV434 human ovarian granulosa
tumor, and PEA1 human ovarian carcinoma were obtained
from the European Collection of Cell Cultures. MCF10a human
nontumorigenic breast epithelia were obtained from Ameri-
can Type Culture Collection, peripheral blood mononuclear
cells (PBMC) were obtained from Stem Cell Technologies, and
primary hepatocytes were obtained from Life Technologies.
HepG2 human hepatocellular carcinoma, MCF7 human breast
adenocarcinoma, THP1 human acute monocytic leukemia,
and JURKAT human acute T cell leukemia cells were from our
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from European Collection of Cell Cultures.
2.2. Cell culture procedures
All cell lines were cultured at 37°C in an atmosphere
containing 5% (v/v) CO2, in Dulbecco’s modified Eaglemedium
without FA (Sigma), supplemented with 10% (v/v) fetal bovine
serum, 2mmol/L glutamine, 10 U/mLpenicillin, and 100 μg/mL
streptomycin. The medium for the MCF10a cell line was
further supplemented with 20 ng/mL epidermal growth factor
and 100 μg/mL hydrocortisone. Themedium for the HMT-3522
S1 cell line was also supplemented with 10 ng/mL epidermal
growth factor and 500 ng/mL hydrocortisone.
2.3. Measurement of BRCA1 and BRCA2 mRNA expression
by real-time reverse transcription polymerase chain reaction
To determine the effect of FA supplementation on BRCA1
and BRCA2mRNA expression, all cell lines were treated with 0,
25, 50, 75, or 100 nmol/L FA for 72 hours before harvesting in TRI
Reagent (Sigma) according to the manufacturer’s instructions.
Background folate concentration derived from fetal bovine
serum was 1.5 nmol/L. Measurement of mRNA expression was
carried out essentially as described previously [38]. Briefly,
complementary DNA was prepared using Moloney-murine
leukemia virus reverse transcriptase (Promega). Real-time
reverse transcription polymerase chain reactionwasperformed
with SYBR Green JumpStart Taq ReadyMix (Sigma) to amplify
BRCA1 and BRCA2 mRNA using QuantiTect Primer assays
(Qiagen) QT00039305 and QT00008449, respectively. mRNA
levels were determined by the standard curve method [39] and
normalized to cyclophilin expression (QuantiTect assay
QT01866137) [38]. All samples were analyzed in duplicate.
2.4. Measurement of BRCA1 and BRCA2 protein expres-
sion by western blotting
BRCA1 and BRCA2 protein levels were assessed in cell lines in
which FA treatment induced significant changes in BRCA1
and/or BRCA2 mRNA expression. Cells were treated with
either 0 or 100 nmol/L FA. Protein extracts were prepared in
50 mM tris pH 8, 150 mM NaCl, 0.5% sodium deoxycholate,
and 1% nonidet-P40 containing 10% (v/v) Protease Inhibitor
Cocktail (Sigma). Protein concentrations were determined
using a Pierce BCA Protein Assay Kit (Thermo Scientific).
Western blot analysis of protein expression was performed as
described previously [40]. Cell extract (25 μg) was resolved by
SDS PAGE using a 4% to 15% polyacrylamide gradient gel (Bio-
Rad) and transferred to PVDF membrane (Amersham) in
25 mM tris pH 8, 192 mM glycine, 20% (v/v) methanol, and
0.1% (w/v) SDS for 3 hours at 4°C. The membrane was blocked
with 5% (w/v) skimmedmilk powder/tris-buffered saline (TBS;
10 mM tris pH 8.0, 150 mM NaCl) containing 0.1% (v/v) Tween
20 for 1 hour at room temperature and then incubated
overnight at 4°C with anti-BRCA1 antibody (1 μg/mL; Abcam)
or anti-BRCA2 antibody (2 μg/mL; Abcam) in 2% (w/v)
skimmed milk powder/TBS/0.1% Tween 20. The membrane
was then washed four times for 10 minutes each in TBS/0.1%
Tween 20 before being incubated with a horseradishperoxidise–conjugated anti-mouse secondary antibody (1:50
000; Sigma) in 2% (w/v) skimmed milk powder/TBS/0.1%
Tween 20 for 1 hour at room temperature. After washing in
TBS/0.1% Tween 20, the protein bands were detected using
SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Scientific) and were visualized on a VersaDoc
4000MP imaging system (Bio-Rad). Protein molecular weights
were determined using a Fermentas Spectra Multicolor Broad
Range protein ladder (Fisher Scientific), and protein band
intensities were analyzed using ImageJ software (NIH).
Anti–β-actin (1:2000; Sigma) was used as the primary antibody
to normalize for differences in protein loading.
2.5. Measurement of BRCA1 and BRCA2 promoter meth-
ylation by sodium bisulphite pyrosequencing
The regions of the BRCA1 and BRCA2 genes that were
analyzed for DNA methylation by pyrosequencing are indi-
cated in Fig. 1. The region of the BRCA1 promoter that was
analyzed has been shown to be unmethylated in normal cells
and hypermethylated in cancer [43], to be involved in the
regulation of transcription [44] and to contain the minimal
promoter [41] and several transcription factor binding sites
[45–47]. The region of the BRCA 2 gene that was analyzed has
previously been shown to be hypermethylated in sporadic
breast cancers [48]. This region encompasses the BRCA2
minimal promoter region [42] and contains a number of
transcription factor binding sites that regulate BRCA2
expression [42,49,50].
The level of methylation of individual CpG dinucleotides in
the BRCA1 (Fig. 1A) and BRCA2 (Fig. 1B) promoters was
measured using bisulphite pyrosequencing essentially as
described previously [38]. Genomic DNA was isolated, and
bisulphite conversion was performed using the EZ DNA
Methylation-Gold kit (ZymoResearch). The bisulphite-modi-
fied DNA was then amplified using the primers listed in
Table 1 with KAPA2G Robust HotStart ReadyMix (Labtech).
Biotinylation of the polymerase chain reaction products
allowed them to be immobilized on streptavidin-sepharose
beads (GE Healthcare), washed and denatured, and then
released into annealing buffer containing the sequencing
primers in Table 1. Pyrosequencing was performed using
PyroMark Gold Q96 CDT reagents (Qiagen) on a PSQ 96MA
machine (Biotage), and the percentage methylation for each
CpG loci was calculated using the PyroQ CpG software
(Biotage). Internal controls were included within each pyro-
sequencing assay to verify bisulphite-conversion efficiency.
Human genomic DNA methylated at 100% of CpG loci
(Millipore) or at 0% CpG loci (Promega) were included for
each assay.
2.6. Measurement of DNA repair
Cells were treated with either 0 or 100 nmol/L FA for 72 hours
before irradiationwithUVC (λ= 254nm) at a dose of 0.1 J/m−2/s−1
for 18 seconds (1.8 J/m2) using a CL-1000 UVX-linker (UVP). Cells
were cultured for a further 0, 1, or 4 hours and then collected in
Ca2+ and Mg2+-free PBS at approximately 105 cells/mL. Cell
viability was determined using trypan blue exclusion (in
all experiments viability was ≥90%). The single cell gel
Fig. 1 – Regions of the (A) BRCA1 and (B) BRCA2 genes that were analyzed by pyrosequencing. Theminimal promoter regions of
BRCA1 [41] and BRCA2 [42] are indicated by the underlined sequences. CpG loci are indicated in bold font and numbered
relative to the transcription start site. Arrows indicates the transcription start sites.
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conditions using a Comet Assay Kit (Trevigen). All steps were
performed in low light level conditions and at 4°C, unless
otherwise stated. Cellswere combinedwithmolten lowmelting
point agarose at 37°C at a ratio of 1:10 (v/v), 50 μL was spread
onto a CometSlide and the agarose was left to adhere for
30 minutes. The slides were immersed in cold lysis solution
overnight and then in freshly prepared, cold alkaline solution
(300 nM NaOH, 1 mM EDTA, pH 13) for 1 hour. Slides were then
placed in a horizontal electrophoresis tank on ice in alkaline
solution and electrophoresis was performed at 15 V (1 V/cm),
300 mA for 1 hour. The slides were washed twice in distilled
water and then in 70% ethanol, before being dried for 20 min at
37°C. SYBR Gold (Life Technologies) was used to stain the DNA
for 30 min at RT, and the slides were then rinsed with distilled
water before being completely dried at 37°C. Comets were
imaged using a Nikon D3100 DSLR camera attached to an
Axiovert 25CFL microscope (Zeiss). For each treatment, at least
50 cells were analyzed using CASP software (CaspLab), and theTable 1 – PCR and pyrosequencing primers
CpGs covered Forward primer Reverse
BRCA1
−567 to −518 ATGGGAATTGTAGTTTTTTTAAAGAGTT AAAAATC
−355 to −300 AGATTATAGTTTTTAAGGAATATTGTGG TAAAATA
−189 to −166 AGGTTAGAGGGTAGGTATTTTAT ACTCTAA
−80 to −19 GGGGTAGATTGGGTGGTTAATTTAGAG CCAATTA
+8 to +44 GGGGTAGATTGGGTGGTTAATTTAGAG CCAATTA
BRCA2
−56 to +7 GTTGGGATGTTTGATAAGGAATTTT CACAAAT
+25 to +102 GTTGGGATGTTTGATAAGGAATTTT CACAAATamount of DNA damage was expressed as the percentage of
total DNA in the comet tail.
2.7. Statistical analyses
Data are expressed as means ± SE. Statistical analyses were
carried out using SPSS (v21, IBM Corporation, Armonk, NY).
FA dose-response groups for each cell line were compared by
1-way analysis of variance (ANOVA) with Dunnett post hoc
test. Pairwise comparisons of protein expression and DNA
methylation were by Student unpaired t test. DNA repair
capacity was compared by 2-way ANOVA with Bonferroni
post hoc test. Differences were considered to be statistically
significant at P < 0.05. For the primary outcome measure,
mRNA expression, a sample size of 10 cultures provided
statistical power of at least 85% for detecting a 10%
difference with a two-tailed probability of <0.05. This sample
size provided at least this level of statistical power for the
other outcomes.primer (biotin labeled) Sequencing primer
CCAATCCCCCACT AGTTTATAATTGTTGATAAGTA
CCTACCCTCTAACCTCTACT ATTGGAGATTTTTATTAGGG
ATTAACCACCCAATCTAC ATGGTAAATTTAGGTAGAATTTTT
TCTAAAAAACCCCACAACC TTATTTTTTGATTGTATTTTGATTT
TCTAAAAAACCCCACAAC GGGAATTATAGATAAATTAAAATTG
CTATCCCCTCAC GGT TTATTTAGG TTTGATTT
CTATCCCCTCAC GAGTTT TTG AAATTAGG
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3.1. Effect of FA supplementation on BRCA1 and BRCA2
mRNA expression
FA treatment of liver cancer cell lines induced cell type–
and cell line–specific effects on BRCA1 and BRCA2 expression.
FA treatment induced a significant increase in BRCA1 and
BRCA2 mRNA expression in the hepatocellular carcinoma cell
line HepG2 (Tables 2 and 3). FA treatment induced a dose-
related increase in BRCA2 expression in hepatocellular PLC/
PRF/5 cells, but did not alter BRCA1 mRNA expression
significantly. In contrast, in FA-treated hepatocellular carci-
noma Huh-7D12 cells, BRCA1 mRNA expression was lower
and BRCA2 expression was unchanged. There was no
significant effect of FA treatment on BRCA1 or 2 mRNA levels
in the liver adenocarcinoma SK-HEP-1 cells or primary
hepatocytes (Tables 2 and 3).
There was no significant effect of FA treatment on BRCA1
or 2 mRNA expression in transformed mammary epithelial
HMT-3522 cells nor on BRCA1 mRNA expression in the
immortalized but nontransformed mammary epithelial
MCF10a cells. BRCA2 expression in MCF10a cells was consis-
tently below the detection limit of the assay (Tables 2 and 3).
FA treatment increased BRCA1 and BRCA2 mRNA expression
in breast adenocarcinoma MCF7 cells. Treatment with FA did
not alter BRCA1 mRNA expression significantly in breast
medullary MDA-MB-157 cells, but decreased the expression of
BRCA2 in a dose-related manner. In contrast, FA treatmentTable 2 – Effect of FA treatment on BRCA1 mRNA expression
Cell line Cell type Relative mRNA exp
FA concentration (n
0 25
Liver
Hepatocytes Primary 100 ± 22.4 ND
SK-HEP-1 Adenocarcinoma 100 ± 6.2 91.6 ± 6.
PLC/PRF/5 Hepatoma 100 ± 4.9 99.6 ± 3.
HepG2 Hepatocellular carcinoma 100 ± 2.4 114.6 ± 2
Huh-7D12 Hepatocellular carcinoma 100 ± 4.1 95.5 ± 4.
Breast
HMT-3522 Transformed epithelial 100 ± 35.8 139.6 ± 3
Hs578T Ductal carcinoma 100 ± 17.0 146.1 ± 1
MCF7 Adenocarcinoma (ER+) 100 ± 7.9 92.3 ± 10
MDA-MB-157 Medulla carcinoma 100 ± 1.4 121.9 ± 8
MDA-MB-231 Adenocarcinoma 100 ± 7.5 124.3 ± 1
MCF10a Nontumorigenic epithelial 100 ± 20.8 88.7 ± 24
Ovarian
A2780 Serous carcinoma 100 ± 31.5 163.8 ± 6
COV434 Granulosa carcinoma 100 ± 72.8 89.8 ± 62
PEA1 Serous carcinoma (ER+) 100 ± 31.6 61.2 ± 21
Leukocyte
PBMC Primary 100 ± 19.7 97.0 ± 16
THP1 Acute monocytic leukemia 100 ± 31.4 150.5 ± 5
JURKAT Acute T cell leukemia 100 ± 18.2 14.3 ± 12
Values are means ± SE (n = 10 replicate cultures). Expression levels were n
were analysed by 1-way ANOVA using Dunnett post hoc correction excep
different from untreated cells are indicated by *P < .05, **P < .01, ***P < .00induced increased BRCA1 and BRCA2 expression at 25 nmol/L,
but the expression of these genes was reduced at higher FA
concentrations.
There was no significant effect of FA treatment on BRCA1
expression in any of the ovarian cancer cell lines tested (Table 2),
whereas BRCA2 expressionwas below the assay detection limit
(Table 3). Treatment with FA decreased BRCA1 mRNA expres-
sion in JURKAT cells, but did not significantly alter its
expression in primary PBMC or THP1 cells (Table 2). There was
no significant effect of FA treatment on BRCA2 mRNA expres-
sion in PBMC, whereas the level of BRCA2 in THP1 and JURKAT
cells was below the detection limit of the assay (Table 3).
3.2. Effect of FA supplementation on BRCA 1 and 2
protein expression
BRCA1 protein expression was not significantly altered in
HepG2 cells exposed to 100 nmol/L FA (Fig. 2A). In contrast, FA
treatment of Hs578T cells induced a significant increase in
BRCA1 protein (Fig. 2B). The level of BRCA2 protein was below
the level of detection in all cells tested (data not shown).
3.3. Effect of FA supplementation on DNA repair
Significant DNA damage was induced in all of the liver cell lines
which were tested (all P < .0001). Treatment with 100 nmol/L FA
had no effect onDNAdamage in any of the cell lines at any of the
time points that were measured (Fig. 3). DNA damage increased
significantly in primary hepatocytes 1 hour after being irradiated
and the amount of damage returned to similar levels prior toression ANOVA
(P)
mol/L)
50 75 100
ND ND 98.1 ± 18.9 .95a
3 90.3 ± 5.3 93.9 ± 6.4 108.1 ± 8.3 .32
1 96.9 ± 5.1 105.6 ± 2.6 107.5 ± 5.9 .45
.6** 116.8 ± 3.1** 113.5 ± 1.7* 115.8 ± 4.3** .003
5 79.0 ± 5.4* 82.0 ± 7.2 98.9 ± 5.0 .024
6.0 143.9 ± 24.0 174.5 ± 32.1 62.9 ± 58.5 .30
1.8 218.1 ± 21.6*** 181.5 ± 14.3* 180.5 ± 22.2* .001
.0 99.6 ± 13.4 66.8 ± 13.3 119.7 ± 10.5 .028
.0 112.2 ± 6.6 108.5 ± 6.2 98.0 ± 6.4 .080
2.8 84.0 ± 4.6 72.4 ± 9.0 77.0 ± 5.0 .0004
.7 ND 64.1 ± 41.1 61.8 ± 27.5 .55
6.0 103.1 ± 32.2 171.4 ± 29.7 131.0 ± 26.4 .52
.3 135.7 ± 52.7 141.1 ± 28.6 139.8 ± 33.5 .91
.6 27.8 ± 8.4 43.1 ± 26.0 95.0 ± 29.2 .19
.3 153.2 ± 23.6 128.7 ± 13.4 119.7 ± 14.2 .197
2.8 22.2 ± 7.7 103.6 ± 43.3 169.7 ± 89.7 .0827
.2* 79.9 ± 36.5 26.8 ± 6.1* 24.8 ± 5.4 .0167
ormalized to reference gene and are relative to untreated cells. Data
t awhere data were analyzed using Student t test. Values significantly
1.
Table 3 – Effect of FA treatment on BRCA2 mRNA expression
Cell line Cell type Relative mRNA expression ANOVA
(P)a
FA concentration (nmol/L)
0 25 50 75 100
Liver
Hepatocytes Primary 100 ± 11.9 ND ND ND 89.9 ± 17.5 .64a
SK-HEP-1 Adenocarcinoma 100 ± 3.5 109.1 ± 13.3 92.8 ± 5.9 113.3 ± 3.0 126.3 ± 13.8 .20
PLC/PRF/5 Hepatocellular carcinoma 100 ± 7.0 100.6 ± 5.4 105.7 ± 5.7 119.2 ± 1.8* 129.2 ± 3.2** .0009
HepG2 Hepatocellular carcinoma 100 ± 4.1 114.2 ± 2.3 112.0 ± 3.7 111.7 ± 3.8 110.2 ± 5.2 .003
Huh-7D12 Hepatocellular carcinoma 100 ± 6.4 101.1 ± 5.6 88.2 ± 3.2 87.2 ± 3.4 94.6 ± 2.3 .14
Breast
HMT-3522 Transformed breast epithelial 100 ± 40.7 148.9 ± 55.1 221.7 ± 85.4 278.1 ± 111.9 120.4 ± 120.4 .51
Hs578T Ductal breast carcinoma 100 ± 18.1 182.9 ± 21.9 334.5 ± 24.9*** 228.5 ± 19.1 246.4 ± 26.3* .0001
MCF7 Breast adenocarcinoma (ER+) 100 ± 10.8 106.0 ± 7.8 123.2 ± 12.6 108.2 ± 8.4 158.0 ± 11.3*** .0024
MDA-MB-157 Medulla
Breast carcinoma
100 ± 4.4 86.6 ± 4.4 72.7 ± 4.6 71.4 ± 4.9 62.2 ± 2.0** .0029
MDA-MB-231 Breast adenocarcinoma 100 ± 9.6 127.9 ± 14.0 110.7 ± 9.8 74.6 ± 10.9 105.6 ± 8.8 .023
MCF10a Immortalized breast epithelial ND ND ND ND ND ND
Ovarian
A2780 Serous carcinoma Undetectable ND
COV434 Granulosa carcinoma Undetectable ND
PEA1 Serous carcinoma (ER+) Undetectable ND
Leukocyte
PBMC Primary 100 ± 23.4 142.4 ± 15.8 214.2 ± 41.8 235.3 ± 25.6 179.5 ± 18.9 .0672
THP1 Acute monocytic leukemia Undetectable ND
JURKAT Acute T cell leukemia Undetectable ND
Values are means ± SE (n = 10 replicate cultures). Expression levels were normalized to reference gene and are relative to untreated cells. Data
were analysed by 1-way ANOVA using Dunnett post hoc correction except awhere data were analysed using Student t test. Values significantly
different from untreated cells are indicated by *P < .05, **P < .01, ***P < .001.
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damage, which were highest immediately after irradiation and
then decreased to baseline damage levels after 4 hours (Fig. 3B).
Conversely, the damage observed in the PLC/PRF/5 cell line
significantly increased with every time point (Fig. 3C).Fig. 2 – Effect of FA treatment on BRCA1 protein expression in H
Hs578T cells treated with 0 nmol/L FA or 100 nmol/L FA for 72 h
anti–β-actin antibodies. Values are means ± SE (n = 5 replicate c
significantly different from untreated cells are indicated by *P < 0Significant DNA damage was also induced in all of the
breast lines that were tested (all P < .0001) (Fig. 4). There was a
significant time × treatment interaction effect on DNA
damage in MCF10a cells (F3,907 = 12.0, P < .0001) (Fig. 4A).
Treatment with 100 nmol/L FA decreased the amount ofepG2 and Hs578T cells. Cell extracts from (A) HepG2 and (B)
ours and analyzed by Western blotting with anti-BRCA1 and
ultures). Data were analyzed using Student t test. Values
.05.
Fig. 3 – Effect of FA supplementation on DNA repair capacity in liver cells. Primary hepatocyte (A), HepG2 (B), and PLC/PRF/5 (C)
cells were treated with 0 nmol/L FA or 100 nmol/L FA for 72 hours, irradiated with 1.8 J/m2 UVC, and DNA damage was
analyzed by Comet assay. Values are means ± SE (n ≥ 50 comets). Data were analyzed by 1-way ANOVA using Bonferroni post
hoc correction. Means without a common letter differ significantly (P < 0.05).
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damage in both treatment groups had returned to baseline
levels after 4 hours (Fig. 4A). There was also a significant
time × treatment interaction effect on DNA damage in Hs578T
cells (F3,911 = 7.2, P < .0001) (Fig. 4B). DNA damage immediately
after irradiation was significantly higher in cells treated with
100 nmol/L FA compared to untreated cells. However, DNA
damage levels were significantly lower in the FA treated cells
than the control group after 1 hour recovery (Fig. 4B). After 4
hours, DNA damage levels for both groups had increased to
similar levels. There was no significant effect of FA treatment
on the induction of DNA damage or recovery in either MCF7 or
MDA-MB-157 cells (Fig. 4C, D).
3.4. BRCA 1 and 2 DNA methylation
We compared baseline methylation levels at 0 nmol/L FA for
all of the cell lines (Figs. 5 and 6). Because of the detection
limit of pyrosequencing assays [52], CpG loci that had
methylation levels of 5% or less were regarded as essentiallyunmethylated. Statistical analysis was only carried out for
loci at which the level of methylation was at least 5% in all the
cell lines tested for a specific tissue.
BRCA1 promoter methylation was below 15% at most CpGs
investigated in all liver cell lines, with small significant differ-
ences (≤5%) between cell lines at specific CpG loci (Fig. 5A).
Methylation of BRCA1 in the breast cancer cells was more
variable than in liver or ovarian cells, or leukocytes (Fig. 5). HMT-
3522 and Hs578T cells significantly higher methylation (≥20%) at
CpG loci−567, −565 and inHMT-3522 cells alone atCpGs−533and
−518 compared with the other breast cell lines for which
methylated was approximately 5% for all CpG loci (Fig. 5B).
There were also small, significant differences (≤5%) between
ovarian cells lines in the level of methylation at CpGs −533 and
−518. Methylation of CpGs −567 and −565 in PBMCs and THP1
cells was significantly higher (20%-30%) at CpGs −567, −565
and at CpGs −533 and −518 (≥10%) compared to the JURKAT
cells (Fig. 5D). However, the level of methylation for all other
CpG lociwas close to or less than 5% for all 3 leukocyte cell lines,
which were tested. DNA methylation across the BRCA2
Fig. 4 – Effect of FA supplementation on DNA repair capacity in breast cells. MCF10a (A), Hs578T (B), MCF7 (C), andMDA-MB-157
cells were treated with 0 nmol/L FA or 100 nmol/L FA for 72 hours, irradiated with 1.8 J/m2 UVC, and DNA damage was
analyzed by Comet assay. Values are means ± SE (n ≥ 50 comets). Data were analyzed by 1-way ANOVA using Bonferroni post
hoc correction. Means without a common letter differ significantly (P < 0.05).
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investigated (Fig. 6). There was no significant effect of FA
treatment on the methylation status of either BRCA1 or BRCA2
in any of the cell lines tested (data not shown).4. Discussion
The findings of previous studies have suggested that the
effect of dietary supplementation with FA on cancer risk is
variable and may depend, in part, upon the nature of the
cancer [2–5,7,8,10–12,53,54]. Our findings are consistent with
these observations. Treatment of cell cultures with FA at
concentrations thatwerewithin the rangewhich can be achieved
in human subjects in vivo [34,55–57] induced differential changes
in the mRNA and protein expression of BRCA1 and BRCA2
between primary and cancer cells derived from the same tissue,
and between cell lines derived from the same cell type. These
findings show for the first time that physiological concentrations
of FA are able to modulate the level of mRNA of two genes thatencodeproteins that are critical formaintenance ofDNA integrity.
None of the primary or nontransformed cells showed significant
FA-induced changes in BRCA1 or BRCA2 mRNA expression. In
contrast, 2 of 4 of the liver cancer cells lines, 3 of 5 breast cancer
cells lines, and 1 of 2 leukemia cells lines, but none of the ovarian
cancer cell lines, showed altered BRCA1 mRNA expression. 2 of 4
liver and 2 of 5 breast, but not ovarian or leukemia, cancer cell
lines showed altered BRCA 2 mRNA expression. Although these
findings do not represent a comprehensive analysis of all possible
cancer cell types that may be derived from these tissues, these
findings support the suggestion that any effect of FA supplemen-
tation on the mRNA expression of BRCA1 or BRCA2 may reflect
the particular type of cancer. Thus these findings are consistent
with and suggest an explanation for the inconsistent reports in
the literature regarding the effect of FA on cancer risk.
4.1. mRNA expression
Treatment with the highest concentration of FA (100 nmol/L)
induced changes in the level of BRCA1 protein in the same
Fig. 5 – BRCA1 DNAmethylation. Themethylation status of individual CpG loci wasmeasured in liver (A), breast (B), ovarian (C),
and leukocyte (D) cell lines without the addition of FA by bisulphite pyrosequencing. Values are means ± SE (n = 10 replicate
cultures). Data were analyzed by 1-way ANOVA using Bonferroni post hoc correction. For each CpG loci, means without a
common letter differ significantly (P < 0.05) (only differences that were ≥5% methylation are marked). Dotted line indicates the
limit of detection of the analysis.
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although this was only significant for the Hs578T cell line. The
effect of varying FA concentration on protein expression was
not tested for practical reasons. AlthoughMCF7 andMDA-MB-
231 cells showed an overall significant effect of FA treatment
on BRCA 1 mRNA expression, pairwise testing did not detect a
significant difference between treated cells and controls, and
so the effect of FA on the levels of BRCA1 protein was not
determined in these cells. Although the BRCA2 transcript was
detected in some cell lines, the level of BRCA2 protein
expression was below the detection limit of the western blot
assay. Nevertheless, these findings suggested that, at least
in some cell types, FA treatment modified the level of both
BRCA1 mRNA and protein. These findings are in contrast
to the effect of supraphysiological FA concentrations on
normal cells [58]. This highlights the importance of usingphysiological concentrations in studies of the effects of
nutrients on cancer-related outcomes in vitro.
4.2. DNA repair
Capacity to repair radiation-induced DNA damage was used
to test whether the changes induced in BRCA1 and/or BRCA2
mRNA or protein expression might be biologically significant.
All cell types showed significant DNA damage as a result of
exposure to nonionizing radiation. However, there were
differences between cells types in their ability to repair DNA
damage. Primary hepatocytes, HepG2, MCF10a, MCF7, and
MDAMB157 cells exhibited DNA repair by 4 hours after
irradiation, the extent of which was greater for the noncancer
cells hepatocytes and MCF10a cells. However, the other
cancer cell lines, PLCPRF5 and Hs578T cells, showed
Fig. 6 – BRCA2 DNAmethylation. Themethylation status of individual CpG loci wasmeasured in liver (A), breast (B), ovarian (C),
and leukocyte (D) cell lines without the addition of FA by bisulphite pyrosequencing. Values are means ± SE (n = 10 replicate
cultures). Data were analyzed by 1-way ANOVA using Bonferroni post hoc correction. For each CpG loci, means without a
common letter differ significantly (P < .05) (only differences that were ≥5% methylation are marked). Dotted line indicates the
limit of detection of the analysis.
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than at earlier time points. Such differences in DNA repair
capacity between cell lines may reflect variation in the
expression and functional activity of other genes involved in
DNA repair. For example, p53 is mutated in Hs578T cells [59]
and CDKN2A in PLC/PRF/5 cells [60]. There was no effect of FA
treatment on DNA repair in liver-derived cells, whereas there
were transient effects of FA treatment on breast tissue-
derived cells. One possible explanation is that although FA
treatment altered BRCA1 or BRCA2 mRNA expression, the
magnitude of this effect maybe too small to result in a
significance change in DNA repair capacity. In cancer cells,
this may have been due to impaired expression of other genes
involved in DNA repair. One implication of these findings is
that dietary FA may have a limited effect on the susceptibility
of liver or breast tumour cells to radiation and hence may not
be a consideration in patients undergoing radiotherapy.4.3. DNA methylation
Variations in folate statushavebeen associatedwith changes in
the DNA methylation status of specific genes [17–20]. Further-
more, DNA hypermethylation of the BRCA1 promoter has been
associated with decreased mRNA expression [26,61,62] and
with sporadic breast cancer [28,30,63,64]. We investigated
whether the changes in BRCA1 or BRCA2 mRNA expression
induced by FA treatment were associated with altered DNA
methylation of these genes. The region of BRCA1 that was
analyzed has been shown previously to be hypermethylated in
some sporadic breast cancer cells, but essentially unmethylated
in others including MCF7 cells, and in PBMC, fibroblasts and
normal mammary epithelium [62]. To our knowledge, there
have not been any study that have reported in detail the
methylation status of individual CpG loci in BRCA 2 using
sequencing techniques. One study reported average
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transcription start site (TSS) [65], but no information is available
about the level of methylation of CpG loci more proximal to the
TSS. We found that the proximal promoter region of BRCA 1
was essentially unmethylated in all cells tested in the absence
of FA treatment. However, specific CpG loci were more highly
methylated in some, but not all, breast, ovary and leukocyte-
derived cells. In contrast, the region of BRCA2 thatwas analyzed
was essentially unmethylated in all cells tested. One possible
implication of these findings is that the background level of
DNA methylation, particularly of BRCA1, may influence the
choice of cell type for studies on epigenetic processes in cancer.
There was no significant effect of FA treatment on the
methylation of the regions of sequenced within the BRCA 1 or
2 promoters. Thus, any effect of FA treatment on the levels of
the transcripts of these genes is unlikely to be mediated
through changes in DNA methylation of these sequences,
although it is possible that other regions could be involved.
However, since the duration of FA treatment was relatively
short, other mechanisms such as changes in histone meth-
ylation could be involved which may subsequently lead to
altered DNA methylation over a longer period [66].5. Conclusions
These findings are consistentwith theuncertainty in the literature
regarding the effects of FA on cancer risk, but indicate that any
effect of FA on BRCA1 or BRCA2 expression may be specific to a
particular cell type. Furthermore, the functional consequences of
FA appear to be modest at least in terms of DNA repair.
Extrapolation of the findings of in vitro studies to patients must be
cautious and limited. However, one possible implication is that,
even if replicated inprimary tumour cells, itmaynot bepossible to
make general recommendations for FA intake in cancer.Competing interests
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